{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for m root_references_citation in Reference Text / Citation (approximate match)
Status:
Possibly Marketed Outside US
Source:
NCT03857425: Phase 4 Interventional Completed Gastritis
(2019)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT04016376: Phase 4 Interventional Active, not recruiting Breast Cancer
(2019)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
G1 SPECIFIED SUBSTANCE
Status:
Other
Class:
G1 SPECIFIED SUBSTANCE
Status:
US Previously Marketed
Source:
SURFAXIN by LEES PHARM HK
(2012)
Source URL:
First approved in 2012
Source:
SURFAXIN by LEES PHARM HK
Source URL:
Class:
G1 SPECIFIED SUBSTANCE
Status:
Investigational
Source:
NCT00879866: Phase 1 Interventional Completed Lung Cancer
(2009)
Source URL:
Class:
CONCEPT
Status:
Investigational
Source:
NCT00725582: Phase 1 Interventional Completed Asthma
(2008)
Source URL:
Class:
CONCEPT
Status:
Investigational
Source:
NCT03094169: Phase 1/Phase 2 Interventional Terminated Solid Tumor, Adult
(2017)
Source URL:
Class:
CONCEPT
Status:
Investigational
Source:
NCT03801915: Phase 2 Interventional Completed Colon Cancer
(2019)
Source URL:
Class:
CONCEPT